Publicado 4 números por año
ISSN Imprimir: 1050-6934
ISSN En Línea: 1940-4379
Indexed in
Breast Cancer and Ovarian Cancer Genetics
SINOPSIS
Breast and ovarian cancers are the second and fifth leading causes of cancer death, respectively, among women in the United States. Individuals with breast cancer have a 20-30% chance of having at least one relative with the disease. However, only 5-10% of the cases are a direct result of germline mutations in highly penetrable genes, such as BRCA1 and BRCA2 (BRCA1/2) as well as genes TP53 and PTEN. Since 1996, genetic testing for these mutations has been clinically available. A strategy for the management of women at increased familial risk of breast and ovarian cancers is described, which includes genetic assessment, chemoprevention, radiologic screening, and clinical and self-examination. Genetic testing should occur within a cancer genetic clinic after genetic counseling. A blood sample allows determination of the presence of the BRCA1 and BRCA2 genes, the TP53 gene, the PTEN gene, and the ATM gene. Tumor examination has identified a growth factor receptor gene, human epidermal growth factor receptor (HER-2).
With regard to diet and lifestyle, women at increased risk of breast cancer could be advised to reduce dietary fat, avoid obesity, decrease alcohol consumption, and take regular exercise. Although chemoprotection is a valuable consideration, it is important to emphasize that the use of Tamoxifen in BRCA1 and BRCA2 mutation carriers is not established, nor is the optimum duration of benefit. An overview of the main outcomes of the current published studies confirms a 38% decrease in breast cancer incidence with Tamoxifen but recommends its use be restricted to women at high risk of breast cancer and low risk for potential side effects. The role of bilateral risk-reducing mastectomy or prophylactic mastectomy has been controversial for several reasons, including the psychosocial significance of the breast in Western cultures, the wide acceptance of breast conservation in surgery for early breast cancer, and the previous lack of data on its efficacy. The surgical procedure should aim to remove substantially all at-risk breast tissue. However, there is a balance between reduction of cancer risk and cosmetic outcome. Bilateral prophylactic oophorectomy can significantly decrease ovarian cancer risk in women who carry BCRA1 mutations. Oophorectomy lowers the risk of breast cancer, even in women who have previously used hormone replacement therapy. There are no published randomized controlled trials examining the effectiveness of mammographic screening in women under 50 years of age with a family history of breast cancer. However, the published studies do suggest that mammographic screening of a high-risk group of women under 50 years of age may detect cancer at a rate equivalent to that seen in women 10 years older with normal risk. Other initial studies also support MRI as having a greater sensitivity than mammography in high-risk women. Breast clinical and self-examination is often advocated, but its effectiveness is unproved, and only one randomized study has been undertaken in women at risk. On the basis of this study as well as one nonrandomized study, it can be concluded that clinical examination as well as mammography are essential in detecting breast cancer. under 50 years of age with a family history of breast cancer. However, the published studies do suggest that mammographic screening of a high-risk group of women under 50 years of age may detect cancer at a rate equivalent to that seen in women 10 years older with normal risk. Other initial studies also support MRI as having a greater sensitivity than mammography in high-risk women. Breast clinical and self-examination is often advocated, but its effectiveness is unproved, and only one randomized study has been undertaken in women at risk. On the basis of this study as well as one nonrandomized study, it can be concluded that clinical examination as well as mammography are essential in detecting breast cancer.
-
Golubovskaya Vita M., Virnig Christopher, Cance William G., TAE226-Induced apoptosis in breast cancer cells with overexpressed Src or EGFR, Molecular Carcinogenesis, 47, 3, 2008. Crossref
-
Kaur M., Radovanovic A., Essack M., Schaefer U., Maqungo M., Kibler T., Schmeier S., Christoffels A., Narasimhan K., Choolani M., Bajic V. B., Database for exploration of functional context of genes implicated in ovarian cancer, Nucleic Acids Research, 37, Database, 2009. Crossref
-
Prochazka M, Hall P, Granath F, Czene K, Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study, British Journal of Cancer, 95, 9, 2006. Crossref
-
de Melo-Martín Inmaculada, Genetic Testing: The Appropriate Means for a Desired Goal?, Journal of Bioethical Inquiry, 3, 3, 2006. Crossref
-
Kim Myoung Ok, Kim Sung Hyun, Lee Sang Ryeul, Shin Mi Jung, Min Kwan Sik, Lee Dong Beom, Lee Sung Won, Kim Kil Soo, Kim Sun Jung, Ryoo Zae Young, Ectopic expression of tethered human follicle-stimulating hormone (hFSH) gene in transgenic mice, Transgenic Research, 16, 1, 2007. Crossref
-
Werner-Lin Allison, Beating the Biological Clock: The Compressed Family Life Cycle of Young Women with BRCA Gene Alterations, Social Work in Health Care, 47, 4, 2008. Crossref
-
Zhang Wei, Becciolini Aldo, Biggeri Annibale, Pacini Paolo, Muirhead Colin R, Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy, Breast Cancer Research, 13, 2, 2011. Crossref
-
Werner-Lin Allison, Formal and Informal Support Needs of Young Women withBRCAMutations, Journal of Psychosocial Oncology, 26, 4, 2008. Crossref
-
Al-Sadoon Mohamed K., Abdel-Maksoud Mostafa A., Rabah Danny M., Badr Gamal, Induction of Apoptosis and Growth Arrest in Human Breast Carcinoma Cells by a Snake (Walterinnesia aegyptia) Venom Combined With Silica Nanoparticles: Crosstalk Between Bcl2 and Caspase 3, Cellular Physiology and Biochemistry, 30, 3, 2012. Crossref
-
Verma Mukesh, Seminara Daniela, Arena Fernando J., John Christy, Iwamoto Kumiko, Hartmuller Virginia, Genetic and Epigenetic Biomarkers in Cancer, Molecular Diagnosis & Therapy, 10, 1, 2006. Crossref
-
DuPree Beth, Breast Health, in Lifestyle Medicine, Second Edition, 2013. Crossref
-
Molina-Montes Esther, Pérez-Nevot Beatriz, Pollán Marina, Sánchez-Cantalejo Emilio, Espín Jaime, Sánchez María-José, Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis, The Breast, 23, 6, 2014. Crossref
-
Pelletier Cory, Speed William C., Paranjape Trupti, Keane Katie, Blitzblau Rachel, Hollestelle Antoinette, Safavi Kyan, van den Ouweland Ans, Zelterman Daniel, Slack Frank J., Kidd Kenneth K., Weidhaas Joanne B., RareBRCA1haplotypes including 3’UTR SNPs associated with breast cancer risk, Cell Cycle, 10, 1, 2011. Crossref
-
Madeira Klesia Pirola, Daltoé Renata Dalmaschio, Sirtoli Gabriela Modenesi, Carvalho Alex Assis, Rangel Leticia Batista Azevedo, Silva Ian Victor, Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development, Molecular Biology Reports, 41, 8, 2014. Crossref
-
Gorodetska Ielizaveta, Serga Svitlana, Levkovich Natalia, Lahuta Tetiana, Ostapchenko Ludmila, Demydov Serhyi, Anikusko Nikolay, Cheshuk Valeriy, Smolanka Ivan, Sklyar Svitlana, Polenkov Serhyi, Boichenko Oleksander, Kozeretska Iryna, The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine, Hereditary Cancer in Clinical Practice, 13, 1, 2015. Crossref
-
Veskimäe Kristina, Staff Synnöve, Tabaro Francesco, Nykter Matti, Isola Jorma, Mäenpää Johanna, Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies, Genes, Chromosomes and Cancer, 54, 5, 2015. Crossref
-
Aleskandarany Mohammed, Caracappa Daniela, Nolan Christopher C., Macmillan R. Douglas, Ellis Ian O., Rakha Emad A., Green Andrew R., DNA damage response markers are differentially expressed in BRCA-mutated breast cancers, Breast Cancer Research and Treatment, 150, 1, 2015. Crossref
-
Gadducci Angiolo, Biglia Nicoletta, Cosio Stefania, Sismondi Piero, Riccardo Genazzani Andrea, Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy, Gynecological Endocrinology, 26, 8, 2010. Crossref
-
Verma Kanika, Kannan Kaavya, V Shanthi, R Sethumadhavan, V Karthick, K Ramanathan, Exploring β-Tubulin Inhibitors from Plant Origin using Computational Approach, Phytochemical Analysis, 28, 3, 2017. Crossref
-
Martínez-Mesa J., Werutsky G., Michiels S., Pereira Filho C.A.S., Dueñas-González A., Zarba J.J., Mano M., Villarreal-Garza C., Gómez H., Barrios C.H., Exploring disparities in incidence and mortality rates of breast and gynecologic cancers according to the Human Development Index in the Pan-American region, Public Health, 149, 2017. Crossref
-
Arroyo Yustos M., Martín Angulo M., Álvarez-Mon Soto M., Cáncer de mama, Medicine - Programa de Formación Médica Continuada Acreditado, 12, 34, 2017. Crossref
-
Sayani Ambreen, Inequities in genetic testing for hereditary breast cancer: implications for public health practice, Journal of Community Genetics, 10, 1, 2019. Crossref
-
Al‐Hussaini Maysa, Ammar Khawlah, Kasasbeh Nour, Sultan Hala, Al‐Omari Amal, Global celebrities' effect on health awareness among Jordanians: A study using the case of Angelina Jolie, Journal of Genetic Counseling, 28, 5, 2019. Crossref
-
Koroth Jinsha, Nirgude Snehal, Tiwari Shweta, Gopalakrishnan Vidya, Mahadeva Raghunandan, Kumar Sujeet, Karki Subhas S., Choudhary Bibha, Investigation of anti-cancer and migrastatic properties of novel curcumin derivatives on breast and ovarian cancer cell lines, BMC Complementary and Alternative Medicine, 19, 1, 2019. Crossref
-
Ren Boxue, Ye Lei, Gong Jianwei, Ren Huanhuan, Ding Yangfang, Chen Xiaoyu, Liu Xiaona, Lu Peng, Wei Fei, Xu Wenjuan, Zheng Qiusheng, Li Defang, Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer, Frontiers in Pharmacology, 10, 2019. Crossref
-
Yoshida Reiko, Watanabe Chie, Yokoyama Shiro, Inuzuka Mayuko, Yotsumoto Junko, Arai Masami, Nakamura Seigo, Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X, Oncotarget, 10, 35, 2019. Crossref
-
Fadda Marta, Chappuis Pierre O., Katapodi Maria C., Pagani Olivia, Monnerat Christian, Membrez Véronique, Unger Sheila, Caiata Zufferey Maria, Galli Alvaro, Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?, PLOS ONE, 15, 10, 2020. Crossref
-
Kardashian Ani, Fehniger Julia, Creasman Jennifer, Cheung Eleanor, Beattie Mary Stanley, A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Cancer in Clinical Practice, 10, 1, 2012. Crossref